QuidelOrtho (QDEL) has drawn fresh investor attention after announcing a long-term supply agreement with Lifotronic Technology, giving the diagnostics company access to additional immunoassay analyzers and more than 70 assays across select markets outside the United States.
See our latest analysis for QuidelOrtho.
That supply agreement arrives at a time when QuidelOrtho’s share price has seen a 7.31% 7 day gain to US$22.74, but its year to date share price return of 20.99% and 1 year total shareholder return of 41.77% indicate that longer term momentum has been weak.
If this immunoassay expansion has you thinking about where else testing and data heavy healthcare could head, it may be worth scanning our list of 28 healthcare AI stocks for more ideas beyond QuidelOrtho.
With QuidelOrtho trading at US$22.74 after a 1-year total shareholder return decline of 41.77% and a reported loss of US$1,131.8m, is this pricing in future growth, or could there be a buying opportunity?
Most Popular Narrative: 34.4% Undervalued
QuidelOrtho’s most followed narrative pegs fair value at about $34.67 per share versus the last close of $22.74, framing the stock as materially discounted and heavily tied to how well its diagnostics portfolio scales globally.
Expansion into international markets such as Latin America, Asia Pacific, and underpenetrated regions like China, where differentiated technology, low market share, and a large runway for immunoassay growth exist, positions QuidelOrtho to capture increased demand stemming from global health system focus on early detection and public health surveillance, which should drive topline revenue growth.
Curious what sits behind that growth runway and fair value gap? The narrative leans on measured revenue gains, improving margins, and a future earnings profile that looks very different to today.
Result: Fair Value of $34.67 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear pressure points, including post pandemic COVID testing declines and product discontinuations, that could keep revenue under strain and challenge margin recovery.
Find out about the key risks to this QuidelOrtho narrative.
Next Steps
Mixed signals here, right? With both risks and potential rewards in play, it makes sense to move quickly, review the details yourself, and weigh up 2 key rewards and 1 important warning sign.
Looking for more investment ideas?
If QuidelOrtho has sparked your curiosity, do not stop here. Use the Simply Wall St screener to uncover other opportunities that could fit your style.
- Spot potential bargains quickly by scanning our list of 49 high quality undervalued stocks that may offer more value for every dollar you put to work.
- Strengthen your watchlist with companies screened for resilient finances using our solid balance sheet and fundamentals stocks screener (41 results) that aim to prioritise stability and disciplined balance sheets.
- Hunt for under the radar opportunities through a screener containing 24 high quality undiscovered gems that focuses on quality businesses many investors might be overlooking.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com